https://www.globenewswire.com/news-release/2023/11/29/2787608/0/en/PreludeDx-to-Present-Data-for-a-Novel-Molecular-Biosignature-to-Predict-Radiation-Therapy-Benefit-in-Early-Stage-Invasive-Breast-Cancer-at-the-2023-San-Antonio-Breast-Cancer-Sympos.html
PreludeDx to Present Data for a Novel Molecular
PreludeDx to Present Data for a Novel Molecular Biosignature to Predict Radiation Therapy Benefit in Early-Stage Invasive Breast Cancer at the 2023 SABCS...
present datanovelmolecular
https://preludedx.com/
Your Biology, Your Decision | PreludeDx DCIS test
Nov 10, 2025 - PreludeDx delivers actionable tools to manage early stage breast cancer with the DCIS test that enables personalized treatment.
biologydecisiondcistest